Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00962377Not ApplicableUnknown

A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation

Role: lead

NCT00351559Not ApplicableCompleted

IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection

Role: lead

NCT00761787Completed

Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY

Role: lead

NCT00671047Unknown

The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study

Role: lead

NCT00751309Terminated

Lung Allograft Rejection Gene Expression Observational (LARGO) Study

Role: lead

All 5 trials loaded